TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10933364

Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg three times a day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Enoximone 25 mg three times a day
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 8881096

Group type: EXPERIMENTAL
Intervention: Mild aversion (painting a bitter substance on nails)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Competing response (performing a competing response when the urge to nailbite occurred)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Self-monitoring alone
Number of subjects: 45
Study: 1546770

Group type: EXPERIMENTAL
Intervention: Six-session enhanced intervention
Number of subjects: 567

Group type: COMPARATOR
Intervention: Two-session informational intervention (early)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Two-session informational intervention (late)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: All groups (including enhanced and informational)
Number of subjects: 567
Study: 3945199

Group type: EXPERIMENTAL
Intervention: Intervention (written information about medications and behavioral strategies)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control (received no intervention)
Number of subjects: 196
Study: 30181143

Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (fish oil)
Number of subjects: 736

Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 736
Study: 25831408

Group type: EXPERIMENTAL
Intervention: Stretching + TENS
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Active Stretching (AS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional Stretching
Number of subjects: 51
Study: 25335329

Group type: EXPERIMENTAL
Intervention: Shugan Jiangu Recipe (SJR), 6 g twice daily for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Caltrate D Tablet (Ca 600 mg and Vit D3 125 IU), one tablet daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Shugan Jiangu Recipe (SJR)
Number of subjects: 38
Study: 22861490

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents
Number of subjects: 53

Group type: COMPARATOR
Intervention: Native stents
Number of subjects: 53
Study: 15838525

Group type: EXPERIMENTAL
Intervention: 1.5 g of DHA and 0.75 g of EPA daily for 6 months
Number of subjects: 19
Study: 11996329

Group type: EXPERIMENTAL
Intervention: Tablet formulation of R115777 (300 or 400 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Capsule formulation of R115777 (300 or 400 mg)
Number of subjects: 24
Study: 9702468

Group type: EXPERIMENTAL
Intervention: Miglitol (BAY m 1099), 100 mg tds
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 7865987

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes of the subject's preferred brand
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ergometry
Number of subjects: 20

Group type: COMPARATOR
Intervention: Psychological stress
Number of subjects: 20

Group type: COMPARATOR
Intervention: Circadian rhythm measurement of salivary cortisol
Number of subjects: 20
Study: 2685532

Group type: EXPERIMENTAL
Intervention: 0.5 g aspirin + 0.3 g calcium carbonate (chewed before swallowing)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.5 g plain aspirin (swallowed)
Number of subjects: 18
Study: 800971

Group type: EXPERIMENTAL
Intervention: 0.25% desoxymethasone ointment
Number of subjects: 56

Group type: COMPARATOR
Intervention: 0.05% fluocinonide ointment
Number of subjects: 56
Study: 30173089

Group type: EXPERIMENTAL
Intervention: Exercise group (≥2 days a week for ≥20 min each day)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No exercise group (<2 days a week for ≥20 min each day)
Number of subjects: 300
Study: 27297851

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.05-0.2 μg/[kg min])
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 24053564

Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 89

Group type: COMPARATOR
Intervention: placebo (two tablets twice daily)
Number of subjects: 89
Study: 22323708

Group type: EXPERIMENTAL
Intervention: Increased oscillatory alpha/beta power over the hemisphere housing the competitor memory trace
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Condition where competitor memory interfered with target retrieval
Number of subjects: 18
Study: 20192140

Group type: COMPARATOR
Intervention: Screw proximal femoral nails
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Helical proximal femoral nails
Number of subjects: 40
Study: 18528794

Group type: EXPERIMENTAL
Intervention: Covered arm (patient's own clothing of maximally 2 mm thickness)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Bare arm
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Arm covered with a standardized cotton sleeve (2 mm)
Number of subjects: 203
Study: 16136931

Group type: EXPERIMENTAL
Intervention: Blood-letting puncture at Twelve Well-Points of Hand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 0
Study: 12412834

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (300 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nefazodone (450 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral delta9-THC (10, 20, 30 mg PO)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Smoked marijuana (0.0%, 1.8%, 2.8%, 3.9% THC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo marijuana (0.0% THC)
Number of subjects: 9
Study: 10048645

Group type: EXPERIMENTAL
Intervention: Plaque index scoring method
Number of subjects: 15

Group type: COMPARATOR
Intervention: Plaque area scoring method
Number of subjects: 15
Study: 7887710

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control
Number of subjects: 415
Study: 2403818

Group type: COMPARATOR
Intervention: 7‐3 regimen (cytosine arabinoside 100 mg/m2/d IV days 1-7, daunorubicin 50 mg/m2/d IV days 1-3)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 7‐3‐7 regimen (same drugs intensified with etoposide 75 mg/m2/d IV days 1-7)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Subset analysis for patients < 55 years with 7‐3 regimen
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Subset analysis for patients < 55 years with 7‐3‐7 regimen
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Subset analysis for patients ≥ 55 years with 7‐3‐7 regimen
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Induction courses for both regimens
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Consolidation courses for both regimens
Number of subjects: 264
Study: 362121

Group type: EXPERIMENTAL
Intervention: Lidocaine prophylaxis
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no lidocaine)
Number of subjects: 13
Study: 30904553

Group type: EXPERIMENTAL
Intervention: Simultaneous implant and CTG placement (test group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Implant placement followed by CTG placement after 3 months (control group)
Number of subjects: 14
Study: 28404450

Group type: EXPERIMENTAL
Intervention: Recovery position
Number of subjects: 59

Group type: COMPARATOR
Intervention: Head tilt and chin lift
Number of subjects: 59
Study: 26080189

Group type: EXPERIMENTAL
Intervention: Closed SRP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open SRP
Number of subjects: 50
Study: 23938312

Group type: EXPERIMENTAL
Intervention: Guided reading group (CBT based self-help resource: What? Me Worry!?!, 8 weeks duration, with telephone support at 2 week intervals)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (information about worry only, one phone call)
Number of subjects: 54
Study: 21207089

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NCCAM-funded chiropractic studies
Number of subjects: 10
Study: 19624476

Group type: EXPERIMENTAL
Intervention: Targeted vector control intervention (focusing on the most productive water container types)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-targeted vector control intervention (attempting to reach all water holding containers)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Targeted vector control intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-targeted vector control intervention
Number of subjects: 8
Study: 16424413

Group type: EXPERIMENTAL
Intervention: Cilomilast, 15 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15142864

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy nondiabetic subjects
Number of subjects: 42
Study: 11355925

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy including high-dose Ara-C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improvements in supportive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future advances in paediatric AML treatment
Number of subjects: 0
Study: 9397386

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 micrograms/day and NETA (170 micrograms/day) given continuously
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 micrograms/day and NETA (350 micrograms/day) given continuously
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 micrograms/day and NETA given sequentially (last 14 days of each treatment cycle)
Number of subjects: 774

Group type: COMPARATOR
Intervention: Oral progestogen (1 mg/day NET or 20 mg/day dydrogesterone) with transdermal estradiol 50 micrograms/day
Number of subjects: 774
Study: 7949797

Group type: EXPERIMENTAL
Intervention: TNF alpha plasma concentration (> 70 pg/ml)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IL‐6 plasma concentration (> 500 pg/ml)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combined TNF alpha and IL‐6 tests
Number of subjects: 55
Study: 3148036

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (12 mg/kg.day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carnitine-free total parenteral nutrition (TPN)
Number of subjects: 16
Study: 31306748

Group type: COMPARATOR
Intervention: TB-related gene-set
Number of subjects: 5512

Group type: COMPARATOR
Intervention: TB (Mendelian Randomization)
Number of subjects: 5512
Study: 29263124

Group type: EXPERIMENTAL
Intervention: High-calorie formula (27 infants, 24 kcal/oz)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard-calorie formula (22 infants, 20 kcal/oz)
Number of subjects: 49
Study: 27626242

Group type: EXPERIMENTAL
Intervention: Standard gastric bypass (alimentary limb, 150 cm)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Distal gastric bypass (common channel, 150 cm)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Distal gastric bypass
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard gastric bypass
Number of subjects: 113
Study: 24670418

Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with AF
Number of subjects: 40
Study: 23452524

Group type: EXPERIMENTAL
Intervention: Ice application (flexible and bendable cold gel packs wrapped in fine cloth sheaths) applied to the chest tube insertion site at the 24th, 28th, 36th, and 40th postoperative hours for 20 minutes.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard postoperative analgesic methods (applied to all patients).
Number of subjects: 40
Study: 20472114

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mcg)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 18786299

Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg BID for 1 week, then 10 microg BID for 1 week)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg QAM for 2 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 61
Study: 15967730

Group type: EXPERIMENTAL
Intervention: Stress echocardiography (SE)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Exercise electrocardiography (ExECG)
Number of subjects: 302
Study: 12828433

Group type: EXPERIMENTAL
Intervention: Argon laser exposure for 5 seconds
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Argon laser exposure for 10 seconds
Number of subjects: 86

Group type: COMPARATOR
Intervention: Visible light control
Number of subjects: 86
Study: 10382130

Group type: EXPERIMENTAL
Intervention: Tubes task (no arbitrary and novel rules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day/night task (verbal output)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 8908384

Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril
Number of subjects: 3657

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 3657

Group type: COMPARATOR
Intervention: Placebo for ACE inhibitor
Number of subjects: 3657

Group type: COMPARATOR
Intervention: Placebo for Vitamin E
Number of subjects: 3657

Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril and Vitamin E
Number of subjects: 3657

Group type: COMPARATOR
Intervention: Placebo for ACE inhibitor and Vitamin E
Number of subjects: 3657
Study: 1874200

Group type: EXPERIMENTAL
Intervention: 3.75% isoflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2.5% halothane
Number of subjects: 36
Study: 6580060

Group type: EXPERIMENTAL
Intervention: Postinduction MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) for an additional 6 months
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Induction BVCPP (BCNU, vinblastine, cyclophosphamide, procarbazine, and prednisone) for 6 months
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 209
Study: 29579136

Group type: EXPERIMENTAL
Intervention: Diagnosis Threat (DT) condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-neutral condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotype lift condition
Number of subjects: 0
Study: 29204914

Group type: EXPERIMENTAL
Intervention: Active LLLT (820 nm wavelength, 30 mW, energy total 18 J)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo LLLT (pLLLT)
Number of subjects: 20
Study: 27338216

Group type: EXPERIMENTAL
Intervention: Emergency Medicine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Internal Medicine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Abdominal Radiology
Number of subjects: 119
Study: 24928832

Group type: EXPERIMENTAL
Intervention: Afatinib (50 mg/day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cetuximab (250 mg/m2/week)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Afatinib (stage II)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cetuximab (stage II)
Number of subjects: 124
Study: 22076647

Group type: EXPERIMENTAL
Intervention: Grafton DBM Matrix with local bone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Autologous ICBG
Number of subjects: 46
Study: 19063830

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 0
Study: 17459185

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (n = 60)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control (n = 60)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nondepressed comparison group (n = 56)
Number of subjects: 60
Study: 14979400

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11341486

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9738217

Group type: EXPERIMENTAL
Intervention: Stapled anastomoses
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hand-sewn anastomoses
Number of subjects: 200
Study: 7996346

Group type: EXPERIMENTAL
Intervention: Intravenously administered immune globulin, 0.5 gm/kg per day for 5 consecutive days (n = 19)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Orally administered methylprednisolone, 30 mg/kg per day for 7 days (n = 19)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Orally administered methylprednisolone, 50 mg/kg per day for 7 days (n = 19)
Number of subjects: 57
Study: 3281399

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg, suppositories, 3 times a day for 3 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (suppositories, 3 times a day for 3 days)
Number of subjects: 46
Study: 1555873

Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuit (Carmeda)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-heparin-coated extracorporeal circuit (Scimed)
Number of subjects: 18
Study: 638969

Group type: EXPERIMENTAL
Intervention: Intralesional BCG therapy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethambutol, rifampin, and prednisolone therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (melanoma not receiving BCG)
Number of subjects: 8
Study: 30826774

Group type: EXPERIMENTAL
Intervention: ianalumab 3 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ianalumab 10 mg/kg
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 28211603

Group type: EXPERIMENTAL
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 2737

Group type: COMPARATOR
Intervention: 6-month dual antiplatelet therapy (DAPT)
Number of subjects: 2737

Group type: COMPARATOR
Intervention: 6-month DAPT
Number of subjects: 2737

Group type: EXPERIMENTAL
Intervention: 12-month DAPT
Number of subjects: 2737
Study: 26100253

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) combined with standard chemotherapy
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1453
Study: 24094982

Group type: EXPERIMENTAL
Intervention: Perioperative low dose vaginal oestrogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 21484217

Group type: EXPERIMENTAL
Intervention: Envelope flap
Number of subjects: 20

Group type: COMPARATOR
Intervention: Triangular flap
Number of subjects: 20
Study: 19847908

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg intravenous infusions every 24 weeks for 96 weeks)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 17715724

Group type: EXPERIMENTAL
Intervention: Patient estimates of overall costs of total knee arthroplasty
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patient estimates of surgeon's fee
Number of subjects: 39
Study: 15555386

Group type: EXPERIMENTAL
Intervention: Reporting and transferring system for tuberculosis patients in general hospitals and township clinics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11487673

Group type: EXPERIMENTAL
Intervention: PTA with Palmaz stent placement
Number of subjects: 53

Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 53
Study: 9771949

Group type: EXPERIMENTAL
Intervention: Toremifene (600 mg/day for 5 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2) without toremifene
Number of subjects: 11
Study: 7828688

Group type: EXPERIMENTAL
Intervention: Histamine administered via a handheld DeVilbiss nebulizer
Number of subjects: 48

Group type: COMPARATOR
Intervention: Methacholine administered via a dosimeter
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Allergen droplet method
Number of subjects: 48

Group type: COMPARATOR
Intervention: Phazet
Number of subjects: 48
Study: 3276283

Group type: EXPERIMENTAL
Intervention: Clomipramine treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: mCPP administration after clomipramine treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: mCPP administration before clomipramine treatment
Number of subjects: 9
Study: 31801395

Group type: EXPERIMENTAL
Intervention: LBEC0101 (etanercept biosimilar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ETN-RP (etanercept reference product)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LBEC0101
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ETN-RP to LBEC0101 switch
Number of subjects: 0

Group type: COMPARATOR
Intervention: ETN-RP
Number of subjects: 0
Study: 31986074

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Number of subjects: 0
Study: 30671976

Group type: EXPERIMENTAL
Intervention: Curcumin (1440 mg/day) for 6 months
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 97
Study: 27780368

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 25867123

Group type: EXPERIMENTAL
Intervention: 1-Hz rLSMS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10-Hz repetitive TMS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 26
Study: 23288387

Group type: EXPERIMENTAL
Intervention: Lithium plus optimized personalized treatment (OPT)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Optimized personalized treatment (OPT) alone
Number of subjects: 283
Study: 21617168

Group type: EXPERIMENTAL
Intervention: A1AT replacement therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18957157

Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Isotonic saline
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no saline treatment)
Number of subjects: 132
Study: 16943174

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) - 10 sessions
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual care (CAU)
Number of subjects: 143
Study: 15116987

Group type: EXPERIMENTAL
Intervention: Endogenous shifts of attention measured using a probe reaction time task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual search tasks
Number of subjects: 0
Study: 10830767

Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 1102